A total of 7,201 veterans with metastatic prostate cancer and CGP were identified. There were 2,484 veterans (median [IQR] age, 72 [67-77] years) with synchronous mHSPC and tissue CGP, which were ...

Erleada significantly reduces the risk of death by 51% in mCSPC patients compared to Nubeqa, without chemotherapy, over 24 months. The study used inverse probability of treatment weighting to ensure ...

For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...

After treatment for metastatic prostate cancer, a drop in prostate-specific antigen (PSA) levels in the blood is an indicator that treatment is working. A recent real-world study indicates that ...

Medically reviewed by Gagandeep Brar, MD Stage 1 and 2 prostate cancer stays in your prostate, and the five-year survival rate is over 99%.Stage 4 prostate cancer is not curable, but treatment can ...

Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 Trial The treatment landscape of metastatic ...

Despite a lack of level 1 evidence, metastasis-directed therapy has been increasingly used for the treatment of oligometastatic prostate cancer based on findings from several randomized phase II ...

Know the questions to ask your doctor about metastatic prostate cancer, such as treatment options, lifestyle changes, and ...

Personalized dosing for late-stage prostate cancer treatments is critical for balancing toxicity with aggressiveness. Yet, ...